Trials showed it extended overall survival 2.6 months. On the...

Trials showed it extended overall survival 2.6 months. On the strength of that some are expecting a market share of $500m. It was approved by the FDA last year.
"Temsirolimus was studied in the most difficult-to-treat patients with advanced renal cell carcinoma: those who have multiple risk factors that have been associated with shortened survival," says Bernard Escudier, M.D., Head of the Immunotherapy Unit, Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France, and an investigator in the TORISEL phase 3 study. "The ability of temsirolimus to provide an increase in overall survival in these patients provides us with a much-needed new option for the treatment of advanced kidney cancer."

TORISEL was studied in a three-arm, phase 3 clinical trial of 626 patients with advanced RCC and three or more of six preselected prognostic risk factors who had received no prior systemic therapy. In the study, TORISEL significantly increased median overall survival by 49 percent compared with interferon-alpha (10.9 months vs. 7.3 months, P=0.0078). TORISEL also was associated with a statistically significant improvement over interferon-alpha in the secondary endpoint of progression-free survival (when the disease does not worsen; 5.6 months vs. 3.2 months, P=0.0042). The combination of TORISEL and interferon-alpha did not result in a significant increase in overall survival when compared with interferon-alpha alone."
http://investor.biospace.com/Engine?Account=biospace&GUID=3898073&Page=MediaViewer&Ticker=WYE

"Wyeth (up $0.74 to $51.64, Charts), based in Madison, N.J., estimates that annual sales of the new drug, Torisel, would peak at $500 million if it is approved by the Food and Drug Administration."
http://money.cnn.com/2006/10/06/news/companies/wyeth/index.htm

Coramsine extends survival in RCC how much??? Its been a couple of years now as far as I know for that late stage RCC patient from the Phase 1.
I hope we hear from the good doctor treating the patient in the US. It would be nice to see Coramsine work twice. Cancer drugs rarely work for everybody, so that is hit and miss, but a very strong indication if they see a response.
Waiting on a phase2 trial. Yawn